BridgeMD
The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial
EU CTIS ID: 2025-524761-25-00
What this study is testing
To compare the number of good quality blastocysts based on the Istanbul consensus workshop criteria (Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Hum Reprod 2011) in two stimulation groups with 10 mcg/day of follitropin delta (equivalent to 150 IU of rFSH) + 150 IU/day of hMG vs 5 mcg/day of follitropin delta (equivalent to 75 IU of rFSH) + 225 IU/day of hMG in advanced age women undergoing PGT-A with a PPOS protocol.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Infertile patients with indication for IVF
- Undergoing preimplantation genetic screening cycles
- Age ≥38 and <42 years old
- AMH 0.5 – 3.5 ng/ml or AFC 5-20 (results of up to one year will be valid)
- BMI 18.5 – 30 Kg/m2
- Normal karyotypes in both partners
You likely can't join if
- Previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol), according to Bologna criteria
- Severe male factor requiring TESE (testicular sperm extraction)
- Administration of any other drug potentially interfering with the treatment
- Contraindication for hormonal treatment
- Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfere with the trial assessment)
- Monogenic disease to be detected with PGT-M
See the full eligibility criteria
- Infertile patients with indication for IVF
- Undergoing preimplantation genetic screening cycles
- Age ≥38 and <42 years old
- AMH 0.5 – 3.5 ng/ml or AFC 5-20 (results of up to one year will be valid)
- BMI 18.5 – 30 Kg/m2
- Normal karyotypes in both partners
- Previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol), according to Bologna criteria
- Severe male factor requiring TESE (testicular sperm extraction)
- Administration of any other drug potentially interfering with the treatment
- Contraindication for hormonal treatment
- Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfere with the trial assessment)
- Monogenic disease to be detected with PGT-M
- Biochemical and/or ultrasonographic evidence of polycystic ovarian syndrome
- Endocrinological and/or autoimmune disorders
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.